One of the major aims of allogeneic haemopoietic stem cell transplantation has been the effective suppression of graft-versus-host disease (GVHD) without loss of a graft-versus-leukaemia effect. For GVHD suppression, one of the most frequently used regimens has been the combination of cyclosporin (CsA) and a short course of methotrexate (MTX) although the optimal usage of these agents remains unclear. Here, we report the results of 55 patients with standard risk leukaemia who have undergone allogeneic transplantation using either bone marrow (n = 48) or G-CSF mobilised peripheral blood stem cells (n = 7) using CsA and MTX for GVHD prophylaxis where the dosage of CsA was regularly adjusted to maintain a trough whole blood level of 95-205 ng/ml for the first 50 days post-transplant. To achieve this level of CsA in the immediate post-transplant period, over 40% of patients required dose adjustments of CsA as a result of sub-therapeutic levels on day +1 post-transplant. The achievement of CsA levels within the therapeutic range was expedited following the introduction of a sliding scale for dose adjustment. With this regimen we have observed a low incidence of acute GVHD with only 11% of patients developing уgrade II disease. With a median follow-up of 66 months (range 8-132) the probability of relapse is only 6.6%. The disease-free survival probability for all patients was 72% at 5 years. These results demonstrate that effective GVHD prevention with CsA and MTX can be achieved without a high risk of recurrent leukaemia provided that rapid attainment of therapeutic CsA levels is achieved and maintenance within a low therapeutic range may help to maximise this effect.
plantation resulting in significant morbidity and mortality. The combination of methotrexate (MTX) and cyclosporin A (CsA) has been found to reduce the incidence and severity of acute GVHD in randomised clinical trials when compared to single agent prophylaxis.
1,2 However, long-term follow-up of controlled trials from Seattle has shown a trend to a higher incidence of relapse in AML patients but not in CML patients treated with combination therapy compared with CsA alone. 2 Although CsA and MTX are now widely used for the prevention of acute GVHD, 3 there is little information concerning the optimal use of these agents to prevent GVHD and as a result there are wide variations in the dosage of CsA used along with a lack of consensus concerning its administration and therapeutic monitoring. In some studies, fixed dosage regimens have been employed with dose modification based on clinical factors such as an elevation of serum creatinine or bilirubin. 4 In other studies, details concerning CsA administration and monitoring are lacking. In an analysis carried out by the EBMT, wide variations were found in CsA dosage and administration, with an initial intravenous dose of 3 mg/kg being most frequently used. 3 Cyclosporin A levels were monitored usually after the initiation of oral therapy but again the target dose ranged markedly from 100 to 800 ng/ml with the concentration most widely accepted being 200-400 ng/ml. 3 The importance of CsA dosage in the immediate post-transplant period determining outcome has been clearly demonstrated in a randomised study comparing low-dose (1 mg/kg/day) vs high-dose (5 mg/kg/day) CsA for the first 20 days post-transplant. 5 In this study patients receiving low-dose CsA had a significantly higher risk of developing grade II-IV acute GVHD, but a significantly lower relapse risk than patients receiving higher dose levels. Overall, patients receiving high-dose CsA had a worse survival as the result of both an increased relapse rate and higher non-GVHD-mediated transplant-related mortality associated with multiorgan toxicity. We have previously reported a low incidence of acute GVHD and a low risk of leukaemic relapse in a group of patients undergoing allogeneic transplantation for leukaemia using CsA and MTX prophylaxis when the dosage of CsA was monitored from day +1 to day +50 to maintain the trough CsA level within a range of 95-205 ng/ml. 6 Here we extend these findings to a large series of patients with a median follow-up of 5 years. The results suggest that careful monitoring of CsA levels at a relatively low level is highly effective in sup-pressing acute GVHD but at the same time maintaining a low risk of recurrent disease.
Patients and methods
From January 1987 to August 1997, 55 consecutive adult patients with standard risk leukaemia or myelodysplasia underwent allogeneic transplantation from fully HLAmatched sibling donors. For this analysis, patients were considered standard risk with acute myeloblastic leukaemia in first complete remission (n = 24), acute lymphoblastic leukaemia in first complete remission (n = 11), chronic myeloid leukaemia in first chronic phase (n = 13), or myelodysplastic syndrome with Ͻ10% blasts in the bone marrow at the time of transplantation (n = 7). All patients received standard conditioning therapy with fractionated total body irradiation (12 Gy in six fractions over 3 days) and cyclophosphamide 60 mg/kg × two doses. The median age of patients was 38.5 years (range 15.8-56.8 years) and 31 were male and 26 female. Twenty-seven transplants involved sex-mismatched donors of whom 16 (29%) were female donors into male recipients. Full details of patient characteristics are shown in Table 1 . Forty-eight patients received donor bone marrow and seven patients received G-CSF mobilised peripheral blood stem cells as previously reported. 7 Antibiotic prophylaxis until 1989 was with oral neomycin and colistin together with nystatin, whereas latterly oral amoxycillin and ofloxacin have been used with fluconazole. In CMV-seropositive recipients or CMV-negative recipients with a seropositive donor high-dose acyclovir (10 mg/kg i.v. 8 hourly) has been administered. Posttransplant haemopoietic growth factors were not routinely given to these patients.
GVHD prophylaxis
All patients received four doses of methotrexate post-transplant at a dose of 15 mg/m 2 on day +1 and 10 mg/m 2 on day +3, +6 and +11. In the presence of severe mucositis the day +11 methotrexate was delayed for 24-48 h. Each dose of MTX was followed 24 h later by intravenous folinic × three doses over 24 h. Cyclosporin A was commenced 36 h prior to the transplant at a dose of 1.5 mg/kg/12 h which was given as a 2-h intravenous infusion and was continued intravenously until the patient could tolerate oral CsA which was usually between day +13 and day +20. Oral CsA was introduced at an initial dose of 5 mg/kg twice daily. CsA levels were measured twice weekly using peripheral venous samples and dosage was adjusted to maintain a whole blood trough level of 95-205 ng/ml and this was continued to day +50. CsA levels were measured using a monoclonal radioimmunoassay (Cyclo-Trac; Incstar, Stillwater, MN, USA). The first trough level of CsA was measured on day +1 posttransplant and if the level was subtherapeutic the dose was increased to maintain the level within the target range. In 1995, as a result of an analysis of early post-transplant CsA levels a new policy was introduced with the use of a sliding scale adjustment of CsA dosage for those patients with subtherapeutic levels at day +1 with an additional assay on day +3 and dose adjustment if levels remained subtherapeutic. The sliding scale was as follows: Ͻ95 ng/ml but Ͼ75 ng/ml, increase dose by 10%; Ͻ75 ng/ml but Ͼ50 ng/ml, increase dose by 20%; Ͻ50 ng/ml increase dose by 30%. Once within the therapeutic range of 95-205 ng/ml, levels continued to be monitored on a twice weekly basis until day +50 when oral CsA tapering was commenced according to the Seattle protocol and therapy was discontinued at 6 months post-transplant unless chronic GVHD supervened. Beyond day +50, CsA levels were not routinely monitored.
Grading of acute GVHD
Acute GVHD was graded uniformly according to the Glucksberg criteria 8 and chronic GVHD was classified as described by Schulman et al. 9 
Statistical analysis
The 2 and rank sum test were used for statistical analyses and Kaplan-Meier plots for time-dependent analyses of survival, transplant-related mortality and relapse.
Results

Analysis of CsA administration
In order to study the efficacy of CsA administration in the immediate post-transplant period, the first six CsA levels were analysed to see if they fell within the therapeutic range. These levels were measured on days +1, +5, +8, +12, +15 and +19 post-transplant, ie during the period when patients were all receiving intravenous CsA therapy. Of the day +1 levels measured on a cohort of 30 patients prior to the introduction of the sliding scale in 1995, 14/30 (47%) were subtherapeutic (Ͻ95 ng/ml). Table 2 shows the number of patients who continued to have subtherapeutic CsA levels on days +5 and +8 and it can be seen that it was not until day +12 when all patients were within or above the therapeutic range. The mean CsA level at day +1 for these patients was 121 ng/ml (range 38-496 ng/ml) rising to 150 ng/ml at day +5 (range 39-369 ng/ml), and 179 ng/ml at day +8, (range 54-424 ng/ml). Re-analysis of CsA levels on a further 20 patients following the introduction of the sliding scale for dose adjustment showed that nine out of 20 patients (45%) were below the therapeutic range on day +1. Following dose adjustment according to the sliding scale, four of these patients achieved therapeutic CsA levels by day +3 and all patients had levels Ͼ95 ng/ml by day +5 and remained within the therapeutic range. In this group, the mean CsA levels on day +1 was 113 ng/ml (range 54-223 ng/ml), rising to 169 ng/ml on day +5 (range 95-389 mg/ml) and was 150 ng/ml on day +8 (range 81-222 ng/ml).
Graft-versus-host disease
The incidence of acute GVHD was low in this study. Fortynine out of 55 patients (92%) had either no or grade I disease, six patients (11%) had grade II or greater and only two patients had grade III-IV disease (Table 3 ). In a previous study of risk factors for the development of grade II-IV GVHD in patients receiving CsA and MTX prophylaxis, a patient age of greater than 40 years was associated with an increased risk whereas higher doses of CsA were associated with a decreased risk. 5 In the current study, 25 out of 55 patients were Ͼ40 years and both cases of grade III GVHD occurred in this group. The risk of GVHD did not a Patient died at 6 months of unexplained acute liver failure without GVHD. appear to be related to donor sex. Thirteen out of 52 evaluable patients have developed chronic GVHD.
Survival
Only two patients have a follow-up of less than 1 year and at a median follow-up of 66.6 months (range 8-132) only four patients have relapsed with a probability of relapse of 6.6% (Figure 1 ). One patient with CML who relapsed is now in molecular CR with no GVHD 18 months following infusion of donor lymphocytes. The other relapses were in AML (n = 2) and ALL (n = 1). One of the patients with AML who relapsed had a history of antecedent myelodysplasia prior to developing AML and relapsed in a myelodysplastic state. The causes of death are shown in Table 3 . The early (Ͻ100 day) transplant-related mortality was low at 5.5%, probably reflecting the low incidence of acute GVHD, and the major cause of death was late transplantrelated mortality which was predominantly seen in older patients. Thus the probability of transplant-related mortality was significantly greater in older patients (Ͼ38.5 years) at 35% compared to 4% for younger patients (P = 0.026) (see Figure 2 ). The disease-free survival for all patients was 72% at 5 years and for younger patients (Ͻ38.5 years) the DFS was 88.8% compared to 67.8% for older patients (P = 0.068) (Figure 3 ).
Discussion
The combination of CsA and MTX has become the most frequently used regimen for prophylaxis of acute GVHD, but there remains little consensus on the scheduling, dosage and monitoring of these drugs. That these factors could have a crucial role in the outcome of the transplant has been amply demonstrated by the divergent effect of high and low dosage of CsA on acute GVHD and relapse. 5 Here we present the results of a 10-year experience of CsA and MTX GVHD prophylaxis regimen where the dose of CsA was adjusted to maintain the CsA level within a relatively low therapeutic range of 95-205 ng/ml. With careful monitoring of CsA levels on a twice weekly basis, we observed a very low incidence of acute GVHD with only two of 55 patients (3.6%) developing Ͼgrade II GVHD. Similarly in a group of 47 patients undergoing HLA-matched transplantation for advanced leukaemia (n = 22), myeloma (n = 20) or lymphoma (n = 5) we also observed a low incidence of grade II-IV GVHD affecting seven out of 45 evaluable patients (17%). These results compare with an incidence of grade II-IV GVHD of 35% seen in a large series of patients transplanted in Seattle 4 where CsA and MTX were used for GVHD prophylaxis, 23% in a randomised study where CsA and MTX were compared with the combination of CsA, MTX and methylprednisolone 10 and an incidence of 29 Ϯ 4% in an analysis performed by the IBMTR on patients transplanted for early leukaemia. 11, 12 Aschan et al 13 showed a low incidence of acute GVHD using CsA and MTX. However, as their study included patients with advanced leukaemia it is difficult to compare the risk of relapse in these two series. Unlike other reported studies, we monitored CsA levels early in the post-transplant period with the aim of rapidly achieving levels within the range of 95-205 ng/ml. Despite this intention, in an analysis of day +1 trough CsA levels carried out in 1995, we found that with an initial starting CsA dosage of 1.5 mg/kg twice daily, 47% of patients had subtherapeutic levels ranging from 38-87 ng/ml, and 23% of patients had persistently low CsA levels by day +5, and only by day +12 did all patients have levels within the established range. The introduction of a sliding scale for dose incrementation of CsA combined with introduction of an additional CsA measurement on day +3 has resulted in earlier achievement of therapeutic CsA levels with all patients achieving the target range by day +5 post-transplant. The finding that almost 50% of patients had subtherapeutic levels on day +1 posttransplant may argue in favour of earlier initiation of CsA pre-transplant at day −2 with the aim of achieving therapeutic levels at the time of marrow infusion, although we have not yet altered our CsA administration protocol in this respect.
Overall Ͼ40% of patients in this study had low levels of CsA in the immediate post-transplant period despite receiving what is widely considered as a standard intravenous dose regimen of CsA. Since in all the patients reported here dose increments were made for levels Ͻ95 ng/ml on day +1 we do not know how many patients would have persisted with low CsA levels if dose adjustments had not been made. However, it is possible that the low incidence of acute GVHD we observed may be related to the rapid attainment of therapeutic CsA levels combined with the administration of full-dose MTX to all patients in this study, since dose reduction of MTX has previously been reported to be an independent risk factor for the development of grade II-IV acute GVHD. 12 The major factor adversely affecting survival was the higher transplant-related mortality (35%) seen in older patients. This mainly related to late deaths (Ͼ100 days) due to chronic GVHD associated with infection, and as a consequence we have recently modified our protocol for patients Ͼ40 years to delay CsA tapering until day +100 and to continue oral CsA until 9 months post-transplant.
The clinical analysis also shows a low relapse probability of 6% which is less than that reported in other studies where MTX and CsA prophylaxis has been employed. To put these results into perspective a recent EBMT analysis reported a 25% relapse probability for patients transplanted for CML in chronic phase who received CsA and MTX prophylaxis. 14 Chao et al 10 reported a relapse risk of 16% at 3 years for a similar group of patients to those reported here transplanted in first remission, and a relapse risk of 24% has recently been reported for AML patients transplanted in first complete remission. 15 Furthermore, an IBMTR analysis of relapse risk in patients receiving CsA and MTX prophylaxis showed a 2-year probability of relapse of 16% for AML in first remission, 23% for ALL in first remission and 7% for CML-CP. 13 Although it is possible that the low relapse risk reported here is in some way related to patient selection our results do suggest that effective GVHD prevention with CsA and MTX can be achieved without a high risk of recurrent leukaemia.
One explanation of the low relapse risk is that CsA levels were maintained within a lower target range (95-205 ng/ml) in our patients than many other centres reporting to the EBMT, where the most common target range used was between 200-400 ng/ml. 3 As we have previously reported, significant dose reductions in oral CsA dosage, reaching a mean of 2.5 mg/kg twice daily by day +50, were necessary to avoid high CsA levels at this stage. 6 These dosage reductions of oral CsA possibly reflect improved absorption of CsA occurring following gut epithelial healing after the first few weeks post-transplant. This careful control of CsA levels in the post-transplant period may have contributed to the low relapse rate since high CsA levels have been clearly associated with a higher rate of recurrent leukaemia. 5 Thus, we conclude that rapid attainment of therapeutic CsA levels together with subsequent maintenance of those levels within a relatively low target range may be associated with both low risk of acute GVHD and low risk of recurrent leukaemia.
